Pre-made Olendalizumab benchmark antibody ( Whole mAb, anti-C5/CO5 therapeutic antibody, Anti-CPAMD4/ECLZB Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-395

Pre-Made Olendalizumab biosimilar, Whole mAb, Anti-C5/CO5 Antibody: Anti-CPAMD4/ECLZB therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Olendalizumab is a novel anti-inflammatory monoclonal antibody targeting complement protein C5a. Upon intravenous administration, anti-inflammatory antibody olendalizumab modulates the complement inflammatory pathway through binding to C5a.This inhibits C5a-mediated signal transduction, and results in the prevention and/or inhibition of both complement-mediated inflammation and cell destruction.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-395-1mg 1mg 3090 30% 2163

Size: 1mg | 10mg | 100mg



Description

Products Name (INN Index) Pre-Made Olendalizumab biosimilar, Whole mAb, Anti-C5/CO5 Antibody: Anti-CPAMD4/ECLZB therapeutic antibody
INN Name Olendalizumab
TargetCO5
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG2
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2015
Year Recommended2017
CompaniesAlexion Pharmaceuticals
Conditions Approvedna
Conditions ActiveAntiphospholipid syndrome;Graft-versus-host disease
Conditions DiscontinuedInflammation
Development Techna